CLNN Key Statistics, Chart & Performance
The current stock price of CLNN is 5.1 USD. In the past month the price decreased by -24.67%. In the past year, price increased by 6.47%.
CLNN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B |
Related stock screener links
About CLNN
Company Profile
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Company Info
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121 US
CEO: Robert Etherington
Employees: 75
Phone: 18016769695
CLENE INC / CLNN FAQ
What does CLNN do?
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Can you provide the latest stock price for CLENE INC?
The current stock price of CLNN is 5.1 USD. The price decreased by -1.54% in the last trading session.
Does CLNN stock pay dividends?
CLNN does not pay a dividend.
What is the ChartMill rating of CLENE INC stock?
CLNN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is CLENE INC (CLNN) stock traded?
CLNN stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for CLENE INC?
CLENE INC (CLNN) operates in the Health Care sector and the Biotechnology industry.
Would investing in CLENE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLNN.
CLNN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLNN. When comparing the yearly performance of all stocks, CLNN is a bad performer in the overall market: 84.08% of all stocks are doing better.
CLNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLNN. CLNN may be in some trouble as it scores bad on both profitability and health.
CLNN Financial Highlights
Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS increased by 32.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLNN Forecast & Estimates
13 analysts have analysed CLNN and the average price target is 32.49 USD. This implies a price increase of 537.14% is expected in the next year compared to the current price of 5.1.
For the next year, analysts expect an EPS growth of 60.08% and a revenue growth -60.09% for CLNN